GYRE GYRE THERAPEUTICS INC

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

Gyre Therapeutics to Present at Sidoti Virtual Investor Conference

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced that Han Ying, PhD, Chief Executive Officer, will be presenting a company overview at the Sidoti August Virtual Investor Conference on Thursday, August 15, 2024, at 10:45 a.m. ET (7:45 a.m. PT).

To register in advance for the presentation webcast, sign up .

A webcast replay will be accessible following the live session on the page of Gyre’s website.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of NASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in NASH is based on the company’s experience in NASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.

For Investors:

Stephen Jasper



EN
09/08/2024

Underlying

GYREGYRE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GYRE THERAPEUTICS INC

 PRESS RELEASE
Free
GYRE GYRE THERAPEUTI...

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global...

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 at 12:30 p.m. ET. To register in advance for the presentation webcast, sign up . The live webcast of the presenta...

September 5, 2025 1 EN
 PRESS RELEASE
Free
GYRE GYRE THERAPEUTI...

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Boar...

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the “Board”) effective August 18, 2025. Dr. Weng has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization (“CRO”), since 2...

August 22, 2025 1 EN
 PRESS RELEASE
Free
GYRE GYRE THERAPEUTI...

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financi...

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update  Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO as Dr. Han Ying transitions to scientific leadership role Revenue of $26.8 million and $48.8 million for the three and six months ended June 30, 2025, respectivelyGAAP basic EPS: $0.00 and $0.04 for the three and six m...

August 11, 2025 1 EN
 PRESS RELEASE
Free
GYRE GYRE THERAPEUTI...

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for ...

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A (“ETA”) receptor antagonist, for the treatment of pulmonary arterial hypertension (“PAH”).This milestone ...

June 10, 2025 1 EN
 PRESS RELEASE
Free
GYRE GYRE THERAPEUTI...

Gyre Therapeutics Announces Closing of its Public Offering and Full Ex...

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it closed its previously announced underwritten public offering of 2,555,555 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 333,3...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch